Exploring 3 31 2015 Session 4 Discussion 2
Let's dive into the details surrounding 3 31 2015 Session 4 Discussion 2.
- Haplogroup compatibility and how mtDNA can influence traits beyond disease Doug Wallace, The Children's Hospital of ...
- Discussion
- Board of Selectmen, March 31. 2015
- Discussion
- Discussion
In-Depth Information on 3 31 2015 Session 4 Discussion 2
Scientific and ethical considerations of mtDNA segregation and the bottleneck phenomenon as it applies to MRT Eric Shoubridge, ... Michio Hirano, Columbia University Medical Center Kirah Fasano, Personal Representative. Potential alternative to preventing transmission of mtDNA diseases: heteroplasmy shift therapy Carlos Moraes, University of ... Patient perspective on MRT Kirah Fasano, Personal Representative.
Panelist field questions from the audience.
That wraps up our extensive overview of 3 31 2015 Session 4 Discussion 2.
